OCX - OncoCyte Operating profit EBITDA

Graphic logo of oncocyte.com (OCX)

Absolute EBITDA dynamics reflect market expectations, with the figure holding around . Current quotes are supported by the leadership of OncoCyte Corporation (OCX) in developing non-invasive molecular rapid tests. The business foundation consists of the Determa platform for the early detection of lung pathologies. Production capacities are based on high-load laboratories equipped with modern sequencing and automated sample preparation equipment.

OCX (OncoCyte) Operating profit before deduction of amortization history from 07/04/2022 to 11/12/2026

OncoCyte (OCX) - metric breakdowns and financial figures

- share price and expert price forecast:
Share Price OncoCyte Inc|OCX - Analyst Consensus Forecast
- market capitalization statistics:
Market Capitalization OncoCyte|OCX - Total Company Value
- book value of equity indicators:
Net Assets per Single Share OncoCyte|OCX - Company Net Assets|Market-to-Book Ratio oncocyte.com|OCX - Aggregate Company Assets
- debt level and financial liquidity data:
Total Debt to Capital Coefficient OncoCyte Corporation|OCX - Long-Term Debt to Capital|Short-Term Debt to Capital Coefficient OncoCyte Corp|OCX - Company Debts|Debts to Net Assets OncoCyte|OCX - Company Long-Term Debt|Short-Term Debt OncoCyte|Immediate Liquidity Ratio oncocyte.com
- net income and valuation multiples indicators:
OCX - Net Profit|Future Profit OncoCyte Corporation|OCX - Price to Earnings Ratio|Projected Price to Earnings Ratio oncocyte.com|OCX - PEG Multiple|Enterprise Value to EBITDA Ratio OncoCyte|OCX - Operating profit before deduction of amortization|Net earnings per one share for the last twelve months OncoCyte|OCX - Net earnings per share for the last 12 months|Year-over-year earnings per share growth rate for the last twelve months oncocyte.com|OCX - Earnings growth in current year|Expected net earnings per share growth next year OncoCyte Corporation
Analysis of all company metrics:OCX OncoCyte Inc
Signature product of OncoCyte Corp.

This indicator captures daily cash flow from operating activities, reflecting the actual balance between cash inflows and offsetting liabilities. Analyzing the actual size of operating profit allows for an assessment of the asset restructuring efficiency at OncoCyte Corporation (OCX), however, the low transparency of management's strategy necessitates caution to avoid overpaying for the asset during periods of temporary liquidity growth.

Competitors of OncoCyte Corporation (OCX)

CAI: Operating profit before amortization|Guardant Health, Inc. - Operating profit EBITDA|VCYT - Operating profit EBITDA|Celcuity (CELC) - Profit before payment of interest, taxes and amortization|GRAL (GRAIL Inc) - Profit before payment of interest, taxes and amortization|Operating profit before deduction of amortization MYGN|Profit before interest, taxes and amortization Castle Bio CSTL|Profit before payment of interest, taxes and amortization Burning Rock Biotech (BNR)|Operating income before deduction of amortization volition.com|Operating profit EBITDA BDSX (Biodesix)|Operating income before deduction of amortization Precipio Inc. (PRPO)|CHEK - Profit before payment of interest, taxes and amortization|Operating income before deduction of amortization Mainz Biomed NV MYNZ